The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This controlled study is designed to evaluate the relapse-free survival of UFT + TAM compared
with CMF + TAM. Patients are randomly assigned to receive either CMF + TAM or UFT + TAM
within 6 weeks after surgery. To assess treatment efficacy, data on recurrence and survival
will be collected for 5 years after surgery. To evaluate the safety, data on adverse events
will be collected during treatment. Patients'quality of life will be assessed by means of a
questionnaire.